Aterovax is a biopharmaceutical company dedicated to improving diagnosis and treatment of atherosclerosis.

News

ATEROVAX sPLA2 Activity Test: an early prognostic marker for patients with ACS symptoms

Read more

Results of the AHA Congress : ATEROVAX's sPLA2 Activity Test significantly improves prediction of cardiovascular events

Read more

 

Aterovax develops innovative solutions to predict , diagnose, prevent and treat cardiovascular disease through its unique understanding of atherosclerosis.

Our first product, ATEROVAX sPLA2 Activity Test, is now available for research use only. The test detects the activity of the enzyme sPLA2, which has been validated as a potent biomarker of the vulnerable or destabilised atherosclerotic plaque.